* Solid Biosciences Inc is expected to show no change in quarterly revenue when it reports results on November 6 (estimated) for the period ending September 30 2024
*
* LSEG's mean analyst estimate for Solid Biosciences Inc is for a loss of 67 cents per share.
* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts had fallen by about 1.8% in the last three months.
* Wall Street's median 12-month price target for Solid Biosciences Inc is 16.50, above its last closing price of $5.75.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Jan. 1 0001 -0.66 -0.66 8.1
Jan. 1 0001 -0.65 -0.64 -0.1
Dec. 31 2023 -1.04 -0.99 -1.00 Missed -1.2
Sep. 30 2023 -1.19 -1.19 -1.05 Beat 11.6
Jun. -1.55 -1.25 18.6
30 2023
Mar. 31 2023 -2.21 -1.50 26.9
Dec. 31 2022 -1.65 -2.82 Missed -70.7
Sep. 30 2022 -2.57 -2.67 -2.71 Missed -1.5
This summary was machine generated November 4 at 21:16 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。